Cambridge Healthtech Institute’s 4th Annual
Next-Generation Immunotherapies
Novel Approaches and Clinical Translation for Oncology & Autoimmunity
19 November 2026
The Next-Generation Immunotherapies conference spotlights cutting-edge approaches to engineer safer, more durable, and more versatile immune-based treatments for cancer and autoimmune disease. Topics include next-gen CAR T, TIL, and NK cell therapies; immunotherapies tailored to solid tumours; and cell-based strategies for autoimmune indications. Additional sessions will examine emerging modalities such as mRNA cancer vaccines, immunocytokines, and rational combination regimens guided by biomarkers and patient selection.
Coverage will include, but is not limited to:
CLINICAL OUTCOMES IN IMMUNOTHERAPY - WHERE ARE WE NOW?
- Comparative clinical data: CAR-T vs. CD20 bsAb vs. TCEs in lymphoma and myeloma
- Long-term survival data from checkpoint inhibitors: 10-year data from PD-1/PD-L1 therapy
- VEGF/PD-L1 bispecifics: mechanism, early data, and market implications
ADVANCES IN IMMUNOTHERAPIES AGAINST SOLID TUMOURS
- Bispecific T cell engagers and TCR T cells in solid tumours - TCR T, CAR NK, RNA-engineered cells, Tregs, γδ T cells, and next-gen TILs
- Adoptive cell-therapy advances
- Oncolytic viruses and cytokine therapies
- Beyond PD-1/CTLA-4: LAG-3+PD-1, TIGIT+PD-L1 outcomes, and emerging TIM-3, VISTA, and PVRIG co-blockade
IMMUNOTHERAPY FOR AUTOIMMUNE AND INFLAMMATORY DISEASES - THE NEW FRONTIER
- CAR T cell therapy for autoimmune disease: Clinical evidence from CD19, BCMA, and CD22 CAR T outcomes
- FOXP3-engineered CAR-Tregs for antigen-specific immune suppression
- CAR-NK and iPSC-derived cell therapies in autoimmunity
- TCR-mimic bispecific approaches for autoimmune disease
- Immunocytokines for autoimmune disease
- Mechanistic rationale for TCEs in autoimmunity: deep B cell and plasma cell depletion vs. CAR-T
- Designing TCEs to mimic CAR-T persistence
- Bi‑specific complement engagers and immune‑modulation strategies for autoimmunity and infection
PREDICTIVE BIOMARKERS AND COMBINATION STRATEGIES
- Biomarker-guided patient selection: CD4 T cell biology, tumor microenvironment profiling for response prediction
- Combination approaches for solid tumors: TCE + co-stim, ADC + checkpoint, TCE + chemo
- Erythrocyte–anti-PD1 conjugates: Phase 1 data in PD-1/PD-L1 resistant advanced solid tumors
- Panel: where do combination immunotherapies work, and for which patients?
The deadline for priority consideration is 9 April 2026.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: